Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Target Cell Response to Hormones01:22

Target Cell Response to Hormones

Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
Hormonal Regulation01:40

Hormonal Regulation

Hormones regulate a significant portion of digestion through activation of the neuroendocrine system. The neuroendocrine system of digestion contains many different hormones all with multiple functions that are both, directly and indirectly, involved in digestion.
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Hormonal Control of the Ovarian Cycle01:30

Hormonal Control of the Ovarian Cycle

The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle.  At puberty, GnRH secretion increases in both frequency and...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From PCOS to PMOS: perspectives on the new nomenclature - Authors' reply.

Lancet (London, England)·2026
Same author

From PCOS to Polyendocrine Metabolic Ovarian Syndrome (PMOS): Implications for Adolescent Gynecologic Care.

Journal of pediatric and adolescent gynecology·2026
Same author

Polyendocrine metabolic ovarian syndrome in pregnancy: pathophysiology and outcomes.

Nature reviews. Endocrinology·2026
Same author

Exploring health information needs and preferences of culturally and linguistically diverse (CALD) women during pregnancy: A mixed methods study.

Patient education and counseling·2026
Same author

From PCOS to PMOS: inclusion of the adolescent voice in setting clinical and research priorities.

The Lancet. Child & adolescent health·2026
Same author

Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process.

Lancet (London, England)·2026
Same journal

Occupational violence and staff safety in general practice.

Australian family physician·2018
Same journal

You should get that mole checked out: Ethical and legal considerations of the unsolicited clinical opinion.

Australian family physician·2018
Same journal

Understanding the decision to commence a dose administration aid.

Australian family physician·2018
Same journal

Psychological distress and risky sexual behaviours among women aged 16-25 years in Victoria, Australia.

Australian family physician·2018
Same journal

A mixed-methods feasibility study of routinely weighing patients in general practice to aid weight management.

Australian family physician·2018
Same journal

The Australian Mid-West Coastal Marine Wound Infections Study.

Australian family physician·2018
See all related articles

Related Experiment Video

Updated: Jun 1, 2026

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

Hormone therapy -- where are we now?

Helena J Teede1, Amanda Vincent

  • 1School of Public Health and Preventative Medicine, Monash University and Head of Diabetes, Southern Health Melbourne, Victoria. helena.teede@monash.edu

Australian Family Physician
|May 21, 2011
PubMed
Summary
This summary is machine-generated.

Menopause management options are explored, focusing on hormone therapy benefits and risks for women aged 50-59. Nonhormonal alternatives and lifestyle changes are also discussed for symptom relief and long-term health.

More Related Videos

Exploring Independent Effects of Follicle-Stimulating Hormone In Vivo in a Mouse Model
05:32

Exploring Independent Effects of Follicle-Stimulating Hormone In Vivo in a Mouse Model

Published on: August 11, 2023

Related Experiment Videos

Last Updated: Jun 1, 2026

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

Exploring Independent Effects of Follicle-Stimulating Hormone In Vivo in a Mouse Model
05:32

Exploring Independent Effects of Follicle-Stimulating Hormone In Vivo in a Mouse Model

Published on: August 11, 2023

Area of Science:

  • Reproductive Endocrinology
  • Women's Health
  • Menopause Management

Background:

  • Menopause, marked by estrogen decline, causes vasomotor and urogenital symptoms in up to 85% of women.
  • Symptoms persist for an average of 5.2 years, with long-term risks including osteoporosis and cardiovascular disease.
  • Menopause management presents challenges for both patients and clinicians.

Purpose of the Study:

  • To review comprehensive menopausal management strategies.
  • To evaluate hormone therapy (HT) and nonhormonal alternatives for symptom relief.
  • To address prevention and treatment of long-term health risks associated with menopause.

Main Methods:

  • Literature review and synthesis of current evidence on menopause management.
  • Analysis of risk-benefit profiles for hormone therapy in women aged 50-59.
  • Exploration of lifestyle modifications, psychological support, and nonhormonal treatments.

Main Results:

  • Hormone therapy offers benefits like relief from hot flashes, urogenital atrophy, and prevention of fractures and diabetes in women aged 50-59.
  • Potential risks of hormone therapy include venous thromboembolism, stroke, cholecystitis, and breast cancer (combined estrogen-progestogen).
  • Nonhormonal options and lifestyle interventions provide alternative management strategies.

Conclusions:

  • Individualized assessment of the risk-benefit profile is crucial for hormone therapy decisions.
  • Comprehensive management includes lifestyle, psychological support, and consideration of both hormonal and nonhormonal treatments.
  • Further research and clear guidelines are needed to navigate complex menopause management.